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ABSTRAKT 
Rekombinantní proteiny patří mezi důležité biofarmaceutické výrobky používané 
v biomedicínském výzkumu a při léčbě lidských nemocí. Aby byla zajištěna biologická 
aktivita, protein musí být náležitě poskládán a post-translačně modifikován. Jelikož může být 
těchto modifikací dosaženo pouze expresí v savčích buňkách, staly se hlavním hostitelem 
expresí komplexních rekombinantních proteinů. Pro výzkumné účely a preklinické studie je 
důležitější rychle vyprodukovat menší množství proteinu, než zdlouhavě hledat linii 
s vysokou produkcí. V případě přechodné exprese genu je protein exprimován během 
několika dní v množství desítek až stovek miligramů na litr. V této diplomové práci je 
popsána přechodná transfekce buněk 293 HEK za použití polyethyleniminů (PEI). Tyto 
buňky byly předem adaptovány na suspenzní kultivaci bez přítomnosti séra. Buňky byly 
transfekovány plasmidem pcDNA5/SEAP, který exprimuje sekretovanou formu lidské 
placentální alkalické fosfatázy (SEAP). K porovnání účinností jednotlivých transfekcí byly 
měřeny koncentrace exprimované fosfatázy v buněčném supernatantu. Základním faktorem, 
který byl optimalizován, byl použitý poměr DNA:PEI; rovněž byly vzájemně srovnány 
účinnosti transfekcí při použití dvou různých polyethyleniminů. Nejvyšší dosažená exprese 
byla 25 mg.l-1 SEAP při transfekci ve 24 jamkových deskách za poměru DNA:PEI 1:7. 
Při stejném poměru jsme při transfekci ve 100 ml čtverhranných lahvích získali expresi 
45 mg.l-1 SEAP. 
ABSTRACT 
Recombinant proteins (r-proteins) are important biopharmaceutical products with applications 
in biomedical research and in the treatment of human disease. To provide biological activity, 
it is necessary for the protein to be properly folded and post-translationally modified. As these 
modifications can be accurately performed only in mammalian cells, they have become 
the major host for complex r-protein expression. For fundamental research or preclinical 
studies, it is more important to produce smaller quantities of the protein in short time span, 
rather than time consuming screening for highly productive cell line. In the case of transient 
gene expression, the protein is produced in few days in tens-of-milligrams per liter range. 
In this thesis, I report successful transient transfection of suspension-adapted HEK 293 cells 
with linear polyethyleneimines (PEIs) in serum-free medium, and subsequent scale-up. 
The cells were transfected with a pcDNA5/SEAP plasmid expressing the secreted form 
of human placental alkaline phosphatase (SEAP). SEAP concentration in cell culture 
supernatants were determined in order to compare efficiencies of individual transfections. 
The crucial factor of DNA:PEI ratio was optimized and two different PEIs were compared. 
At the optimal conditions, production of 25 mg.l-1 of SEAP at the 24 well plate scale at 
DNA:PEI ratio of 1:7 (w/w) was achieved. The procedure was scaled up, yielding 45 mg.l-1 of 
SEAP in 25 ml of medium in agitated square-shaped bottles of nominal volume of 100 ml at 
the same DNA:PEI ratio. 
KLÍČOVÁ SLOVA 
Přechodná transfekce, buňky HEK 293, polyethyleniminy, sekretovaná alkalická fosfatáza  
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Transient transfection, HEK 293 cells, polyethyleneimines, secreted alkaline phosphatase 
 3
KYSELÁ, H. Optimization of recombinant protein production in animal cell culture. Brno: 
Brno University of Technology, Faculty of Chemistry, 2008. 56 p. Head of diploma thesis 
Mgr. Mojmír Ševčík, Ph.D. 
 
 
 
 
 
DECLARATION 
I declare that the diploma thesis has been worked out by myself and that all the quotations 
from the used literary sources are accurate and complete. The content of the diploma thesis is 
the property of the Faculty of Chemistry of Brno University of Technology and all 
commercial uses are allowed only if approved by both the supervisor and the dean of the 
Faculty of Chemistry, BUT. 
 
................................................  
Student’s signature 
 
 
 
 
I owe deep gratitude to Mgr. Mojmír Ševčík, 
Ph.D. for his constructive supervision and 
critical reviewing of the manuscript. 
The completion of this thesis would not have 
been possible without Petr Orság, whom I thank 
for guiding me through the practical issues of 
laboratory work. Special thanks belong to 
BioVendor-Laboratory medicine inc. for 
generous technical support. 
 4
TABLE OF CONTENTS 
1. Introduction ............................................................................................................................ 7 
2. Goal of the Thesis .................................................................................................................. 8 
3. Theoretical Part ...................................................................................................................... 9 
3.1 Recombinant Protein Therapeutics .................................................................................. 9 
3.1.1 Monoclonal antibodies ............................................................................................ 11 
3.2 Plasmids ......................................................................................................................... 12 
3.3 Production in Different Hosts ........................................................................................ 13 
3.4 Animal Cell Culture ....................................................................................................... 14 
3.4.1 HEK 293 Cells......................................................................................................... 15 
3.5 DNA Delivery Methods ................................................................................................. 16 
3.6 Transient Transfection ................................................................................................... 17 
3.7 Poly(ethylenimine) ......................................................................................................... 18 
3.8 Media .............................................................................................................................. 20 
3.9 Secreted Alkaline Phosphatase (SEAP) ......................................................................... 20 
4. Materials and Methods ......................................................................................................... 21 
4.1 Chemicals ....................................................................................................................... 21 
4.2 Instruments ..................................................................................................................... 21 
4.3 Cell Culture .................................................................................................................... 22 
4.3.1 Adaptation Phase ..................................................................................................... 22 
4.3.2 Suspension Cultivation ............................................................................................ 22 
4.3.3 Freezing the Cells .................................................................................................... 23 
4.4 Plasmid DNA ................................................................................................................. 23 
4.4.1 Preparation............................................................................................................... 23 
4.4.2 Purification .............................................................................................................. 24 
4.5 Transfection .................................................................................................................... 26 
4.5.1 Transfection Agents ................................................................................................ 26 
4.5.2 Transfection Process................................................................................................ 26 
4.6 Reporter Protein Quantification ..................................................................................... 27 
4.7 Evaluation of Results ..................................................................................................... 28 
5. Results .................................................................................................................................. 29 
5.1 Effect of time on SEAP Production ............................................................................... 29 
5.2 Effect of DNA:PEI Ratio on Transfection Efficiency ................................................... 30 
5.3 Effect of DNA:PEI-MAX Ratio on Transfection Efficiency ......................................... 32 
5.4 Other Experiments ......................................................................................................... 34 
5.4.1 Effect of Transfection Buffer .................................................................................. 34 
5.4.2 The Cell Density One Day Pre-transfection ............................................................ 35 
5.4.3 Transfection in Square-shaped Bottles .................................................................... 36 
 5
6. Discussion ............................................................................................................................ 37 
6.1 Comparison of Transfection Agents .............................................................................. 37 
6.2 Scaling up ....................................................................................................................... 37 
6.3 Other Improvements ....................................................................................................... 38 
7. Conclusions .......................................................................................................................... 39 
8. Perspectives .......................................................................................................................... 40 
9. References ............................................................................................................................ 41 
10. Abbreviations ..................................................................................................................... 45 
11. Appendices ......................................................................................................................... 46 
11.1 BV293s Medium Composition .................................................................................... 46 
11.2 DMEM/F-12 Medium Composition ............................................................................ 47 
11.3 Qiagen Buffers Composition ........................................................................................ 48 
11.4 Statistics ....................................................................................................................... 49 
11.4.1 Program R : ........................................................................................................... 49 
11.4.2 Effect of DNA:PEI Ratio on Transfection Efficiency ........................................... 49 
11.4.3 Effect of DNA:PEI-MAX Ratio on Transfection Efficiency ................................ 54 
11.4.4 Transfection Agents Comparison .......................................................................... 56 
11.4.5 Effect of Transfection Buffer ................................................................................ 56 
11.4.6 Transfection in Square-shaped Bottles .................................................................. 56 
 
 6
1. INTRODUCTION 
The Recombinant DNA technique was engineered in 1973. This and many other advances in 
molecular biology and genetic engineering have led to enormous progress in the ability to 
understand the bio-molecular roots of human disease.  
One of the first practical applications of this technique was the production of human insulin in 
E. coli. Before it was possible to use the recombinant DNA technique, patients with insulin-
deficiency had been treated with insulin isolated from animal pancreases, which could have 
caused allergic reaction as these preparatives were usually not purified sufficiently. 
Recombinant proteins (r-proteins) are important biopharmaceutical products with applications 
in biomedical research and in the treatment of human disease. To provide biological activity, 
it is necessary for the protein to be properly folded and post-translationally modified. As these 
modifications can be accurately performed only in mammalian cells, they have become 
the major host for complex r-protein expression.  
For fundamental research or preclinical studies, it is important mainly to produce smaller 
quantities of the protein in short time span rather than time consuming screening for highly 
productive cell line in case of stable transfection. This way, the protein is produced in few 
days in tens-of-milligrams per liter range. 
There is a great potential in production of therapeutics this way, therefore this work deals with 
transient transfection of mammalian cell line in order to produce r-proteins. 
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2. GOAL OF THE THESIS 
 According to the previous research, it is known that the transient transfection can produce up 
to tens of milligrams of recombinant protein in few days. The major goal of this work was to 
optimize and describe a transient transfection system for suspension-adapted cells in serum-
free medium. After finding the optimal conditions, the goal was to prove whether the system 
could be scaled up.  
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3. THEORETICAL PART 
In early 1970s, advances in molecular biology and genetic engineering have led to enormous 
progress in the ability to understand the bio-molecular roots of human disease.  
The Recombinant DNA technique was engineered by Boyer and Cohen in 1973 (Cohen et al., 
1973). They were able to create a transgenic bacterium by isolating and amplifying genes or 
segments of DNA and inserting them into another cell. The recombinant DNA technology 
was made possible mainly by the discovery of restriction endonucleases by Werner Arber, 
Daniel Nathans and Hamilton Smith, for which they received the Nobel Prize in Medicine 
in 1978.  
One of the first practical applications of this technique was a production of human insulin 
after inserting human DNA into E. coli by Eli Lilly in 1982. Before the recombinant DNA 
technique was able to be used, patients with insulin-deficiency have been treated with insulin 
isolated from animal pancreases, which could have caused allergic reaction as these 
preparatives usually have not been purified sufficiently. The bovine insulin is almost identical 
to human (difference in three amino acids), the porcine insulin differs from the human one 
only in one amino acid.  
The first recombinant protein product from mammalian cells which achieved market approval 
was the human tissue plasminogen activator, produced by Genentech in 1986. 
This breakthrough led to a wider use of this technique to produce proteins and mainly 
therapeutics which were until then possible to obtain only by isolation from animals or plants.  
Through the use of recombinant DNA, genes that are identified as important, can be amplified 
and isolated for use in other species or applications. Recombinant proteins (r-proteins) are 
expressed after an introduction of foreign DNA sequence to a host organism (bacteria, yeasts, 
and insect, plant or mammalian cell lines). 
 
3.1 Recombinant Protein Therapeutics 
The term “biotechnology” was introduced in 1917 by Karl Ereky. At that time it meant “all 
lines of work by which products are produced from raw materials with the aid of living 
things”. Next step in a definition of biotechnology was year 1961. Carl Göran Hedén 
recommended changing the name of the magazine where findings from applied microbiology 
and industrial fermentation were published from the Journal of Microbiological and 
Biochemical Engineering and Technology to Biotechnology and Bioengineering (Glick and 
Pasternak, 2003). 
When recombinant DNA technology was discovered, it was forecasted that wide range of 
human therapeutics would be able to be synthesized in sufficient quantities. Until now, more 
than 1000 of complementary DNAs (cDNAs) coding various proteins potentially treating 
human diseases, have been cloned (Glick and Pasternak, 2003). 
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Most of these sequences have been expressed in host cells, and currently around 750 are 
undergoing clinical trials for the treatment of various human diseases. More than 80 of these 
biotechnology drugs have been approved for use in the United States of America and 
the European Union (Glick and Pasternak, 2003). However, it will be several years untill 
many of the other proteins are commercially available, because medical products must first be 
tested rigorously in animals and then undergo thorough human trials before being approved 
for general use.  
The major advantage of the recombinant proteins as therapeutics is their higher efficacy and 
fewer side effects than other pharmaceutical products - they can be more specifically targeted 
to the cause of the disease, rather than the treatment of its symptoms. 
The therapeutic protein market was valued in excess of 57 Billion US$ in 2006 and according 
to projections, it would grow at a compound annual growth rate of 12,83 % till 2010. The 
market is now dominated by monoclonal antibodies (with double-digit growth projected for 
future); the segment is expected to reinforce its dominant position. Insulin, Interferon Beta, 
granulocyte-colony stimulating factor and coagulation factors are also showing double-digit 
growth rates. (Global Protein Therapeutics Market Analysis, RNCOS, 2006, Bharat Book 
India, bharatbook.com) 
To date, all r-proteins expressed in mammalian cells are produced in stably transfected cell 
lines. This is standard approach for market-scale production; r-proteins produced by large-
scale transient transfection may however gain regulatory approval in the future. 
Some of biotech’s most celebrated successes besides antibodies include: 
• vaccines 
• anticoagulants 
• erythropoietins  
• interferons 
• interleukins 
• insulin 
• blood-clotting factors 
• colony-stimulating factors  
• growth hormones 
• plasminogen activators 
• reproductive hormones 
• therapeutic enzymes  
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3.1.1 Monoclonal antibodies 
Antibodies constitute the most rapidly growing class of human therapeutics and the second 
largest class of drugs after vaccines. They are the most important mammalian expression 
products on the market. There are very successful companies based on the antibodies 
production as Genentech, Amgen, MedImmune, Novartis and many others.  
Antibodies are highly specific, naturally evolved molecules that recognize and eliminate 
pathogenic and disease antigens. They are proving to be very useful as diagnostic, imaging, 
and therapeutic reagents in clinical medicine. Initially, monoclonal antibodies were used 
primarily as in vitro diagnostic reagents. There are many monoclonal antibody diagnostic 
reagents available such as products for detecting pregnancy, diagnosing numerous pathogenic 
microorganisms, measuring the blood levels of various drugs, matching histocompatibility 
antigens, and detecting antigens shed by certain tumors.  
 
Figure 1. Schematic diagram of structure of immunoglobulins (derived from amino acid sequencing 
studies). Each heavy and light chain in an immunoglobulin molecule contains an amino-terminal 
variable (V) region (aqua and tan, respectively) that consists of 100–110 amino acids and differs from 
one antibody to the next. The remainder of each chain in the molecule—the constant (C) regions 
(purple and red) - exhibits limited variation that defines the two light-chain subtypes and the five 
heavy-chain subclasses. Some heavy chains (γ, δ, and α) also contain a proline-rich hinge region 
(black). The amino-terminal portions, corresponding to the V regions, bind to antigen; effector 
functions are mediated by the other domains. The μ and ε heavy chains, which lack a hinge region, 
contain an additional domain in the middle of the molecule. From Kindt et al., 2003. 
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 Figure 2. Monoclonal antibody production: the conventional polyclonal antiserum produced in 
response to a complex antigen contains a mixture of monoclonal antibodies, each specific for one of 
the four epitopes shown on the antigen (inset). In contrast, a monoclonal antibody, which is derived 
from a single plasma cell, is specific for one epitope on a complex antigen. The outline of the basic 
method of obtaining a monoclonal antibody is illustrated here. From Kindt et al., 2003. 
 
3.2 Plasmids 
Plasmids are extra chromosomal self-replicating circular forms of DNA present in most 
bacteria. They contain genes related to catabolism and metabolic activity and allow 
the bacterium to survive and reproduce in conditions present in other species 
and environments. These genes usually represent characteristics of resistance to antibiotics 
and bacteriophages and some heavy metals.  
A plasmid vector is made from natural plasmids by removing unnecessary segments 
and adding essential sequences. Plasmids make excellent cloning vectors for various 
laboratory techniques, including recombinant DNA. Plasmid vectors contain three common 
features:  
• replicator 
• selectable marker 
• cloning site 
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The replicator or "ori" refers to the origin of replication with regard to location and bacteria 
where the replication begins. The marker refers to a gene that usually contains resistance to 
an antibiotic, but may also refer to a gene that is attached alongside the desired one, such as 
that which confers luminescence to allow identification of successfully recombined DNA. 
The cloning site is a sequence of nucleotides representing one or more positions where 
cleavage by restriction endonucleases occurs. 
The standard mammalian expression vector has a eukaryotic origin of replication, often 
derived from an animal virus, and one from E. coli. Selectable marker genes for either 
eukaryotic and prokaryotic cells are a part of the vector. The elements that regulate 
the transcription of the gene of interest originate from animal viruses or mammalian genes 
(Glick and Pasternak, 2003). 
 
 
Figure 3. Plasmid Vector (Lasic, 1998). The vector contains E. coli origin of the replication, 
the ampicilin resistance gene, marker gene under control of promoter, origin of the replication in 
eukaryotic cell and the selection marker.  
 
3.3 Production in Different Hosts 
There are several ways to obtain r-proteins. Either the host organisms can be prokaryotic 
and then the process is called transformation, or eukaryotic in process of transfection.  
Escherichia coli is the most widely used host for production of r-proteins as it is well-
characterized bacteria-both genetically and physiologically (Baneyx, 1999; Glick and 
Pasternak, 2003). This production system has many advantages as low cost, short doubling 
time, capacity for high level expressions and the ease of genetic manipulations (Dai et al., 
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2005). On the other hand, proteins expressed in bacterial cells usually lack proper folding, 
correct post-translational modifications or have poor solubility (Clark, 2001). 
Saccharomyces cerevisiae is a significant research organism, mainly as a model system for 
eukaryotic organisms, including humans. They grow fast and are still easier to genetically 
manipulate then the other eukaryotic systems. They perform a limited spectrum of post-
translational modifications as glycosylation (Eckart and Bussineau, 1996) but they lack other 
ones.  
The insect cell lines can be cultivated at high densities. They are usually transfected by 
an infection via a recombinant baculovirus, but the r-proteins are usually inactive due to 
the fact that insect cells lack pro-protein convertases. The r-proteins are sometimes insoluble 
and they form aggregates inside the cell (Kost and Condereay, 1999). 
Plant cells grow slowly and the r-proteins show different patterns in glycosylations but they 
are an optimal system for modeling different environmental conditions and its consequences. 
Transgenic plants were also generated. They are easy to cultivate and cost-effective, however, 
the subsequent protein isolation and purification is significantly more difficult than from 
the cells grown as a suspension (Hood and Jilka, 1999). 
Mammalian cells provide proteins that posses relevant post-translational modifications 
and are folded properly, so these systems are used for the production of r-proteins for 
pharmaceutical and research use. The drawback of such a system is that these cells require 
expensive media; they grow slowly and are susceptible to infection with mammalian viruses 
which lead to contamination of the product. 
 
3.4 Animal Cell Culture 
Animal cell culture is cultivation of animal cells outside the tissue (ex vivo) from which they 
were isolated. The cultivation is carried out under laboratory conditions which should mimic 
the in vivo environment: typically, the cells are grown at 37°C, 5% CO2 in a cell incubator. 
There is a major requirement for asepsis, sterility and controlled environment: any 
contamination with bacteria or yeast would cause cell infection and cell death. Bacteria 
or yeast (or both, resp.) would utilize the nutrients from the medium and as they grow faster 
with fewer requirements, they would grow over the animal cells. 
Some cells naturally live without attaching to a surface, such as cells that exist in 
the bloodstream. Others require a surface, such as most cells derived from solid tissues.  
As cells continue to divide in culture, they generally grow to fill the available area or volume. 
This can generate several issues: 
• Nutrient depletion in the growth media. 
• Accumulation of dead cells. 
• Cell-to-cell contact can stimulate cell cycle arrest, causing cells to stop dividing.  
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In order to restock nutrients and avoid the accumulation of potentially harmful metabolic 
byproducts and dead cells, the medium has to be changed and the cells passaged. 
Primary cells are the cells cultured directly from a subject. However, most primary cell 
cultures have a short lifespan: after a limited number of population doublings, these cells 
undergo the process of senescence and stop dividing. On the other hand, an established cell 
line has the ability to proliferate indefinitely. This ability was obtained either by random 
mutation or deliberate modification, such as artificial expression of the telomerase gene.  
There are numerous well established immortal cell lines representative of the particular cell 
types. Among others, following cell lines are often used in research laboratories. 
Human-derived cell lines: 
• HEK-293 (human embryonic kidney): epithelial cells derived from human kidney cells 
• HeLa (Henrietta Lacks): epithelial cells derived from cervical cancer cells 
Other: 
• CHO is cell line derived from Chinese Hamster ovary (CHO) cells. CHO cells are 
used in studies of genetics, toxicity screening, nutrition and gene expression, 
particularly expression of recombinant proteins. 
• 3T3 is a fibroblast cell line, obtained from Swiss mouse embryo tissue, often used in 
the cultivation of keratinocytes 
 
3.4.1 HEK 293 Cells 
HEK 293 cells were generated in 1970s by a transformation of primary human embryonic 
kidney cells with the adenovirus type 5 genes in the laboratory of Alex Van der Eb in Leiden, 
Holland. The human embryonic kidney cells were obtained from a healthy aborted fetus and 
originally cultured by Van der Eb, and the transformation by adenovirus was performed by 
Frank Graham (Graham et al., 1977). The “HEK“ stands for human embryonic kidney and 
the number 293 represents the fact, that it was a result of Graham's 293rd experiment. 
Suspension-adapted HEK cells are now used for r-protein expressions as they can be readily 
transformed with plasmid DNA (Wurm and Bernard, 1999). 
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Figure 4. HEK 293F cells cultivated as suspension culture in BV293s medium in 250 ml square-
shaped glass bottle (40-fold  magnification). 
HEK cells are not a particularly good model for normal cells, cancer cells, or any other kind 
of cell that would be a fundamental object of the research. However, they are easy to work 
with, they are uncomplicated to culture and to transfect, and so can be used in experiments in 
which the behavior of the cell itself is not of interest. Typically, these experiments involve 
transfecting in a gene (or combination of genes) of interest, and then analyzing the expressed 
protein. The widespread use of this cell line is due to its extreme transfectability by the 
calcium phosphate method. 
 
3.5 DNA Delivery Methods 
There are two main approaches of the gene delivery: viral and non-viral vectors. The non-
viral method could be further divided into two areas: mechanical (e. g. intracellular injection 
of DNA or continuous electroporation) and non-mechanical.  
The methods of non-mechanical gene delivery share the same principle of formation of 
positively charged nanoparticles which can enter the cell after binding to the negatively 
charged cell surface.  
The calcium phosphate (CaPi) method is based on the co-precipitation of DNA with calcium 
phosphate (Jordan et al., 1996) while lipofection and polyfection are based on the compaction 
of DNA with liposomes and cationic polymers, resp. These transfection agents are believed to 
condense the DNA into compact particles, which facilitates the interaction between 
transfection particles and cellular surface, stimulating the internalization of the carrier-DNA 
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complex. However, a high percentage of the DNA that enters the cell is degraded before it 
reaches the nucleus (Godbey, Barry et al., 2000).  
After the uptake by endocytosis, the DNA must escape the endosome to be released into the 
cytosol and enter the nucleus. For each transfection method, the mechanisms involved may 
differ. Also, the efficiency of gene delivery by CaPi, lipofection and polyfection has been 
shown to be cell cycle-dependent (Lechardeur, Sohn et al., 1999; Brunner, Furtbauer et al., 
2002; Mannisto, Ronkko et al., 2005). Transfection with liposomes and branched PEI is more 
efficient when added to cells in late S phase (Grosjean, Batard et al., 2002). These 
observations indicate that for all of these transfection methods, plasmid DNA probably enters 
the nucleus after the breakdown of the nuclear membrane during mitosis. The exact 
mechanisms involved in these events remain to be investigated. 
 
3.6 Transient Transfection 
Stable expression technologies require the recombinant gene to be incorporated into the host 
DNA. The subsequent r-protein production process is based on the isolation, characterization 
and expansion of a highly productive clonal cell line from a pool of transfected cells. This 
process is rather lengthy and may take up to 18 months to complete. This technology delivers 
kilograms of complex proteins from mammalian cells; however, the development of these 
technologies requires considerable investment in time, human resources and bioreactor 
equipment (Muller, 2005). 
On the other hand, for various purposes smaller quantities of r-proteins are sufficient: it may 
be frequently necessary to evaluate high number of proteins (or different variants of the same 
protein) as potential pharmaceutics; lower amounts will be required for the application in 
individualized medicine, and it is also an efficient source of r-proteins required for subsequent 
research (Muller-Zellenberg and Muller, 2005). 
The thought of transient systems for production of milligram to gram quantities of proteins is 
rather new. With better technologies for mammalian cells growth and with better nucleic acid 
transfer systems, there is a good chance to launch the transient expression in mammalian cells 
beyond the laboratory scale (Wurm, Bernard, 1999). 
Using low cost DNA delivery agents as calcium phosphate (Jordan  et al., 1996), 
polyethyleneimine (Ehrhardt et al., 2005) on cultures of mammalian cells in volumes ranging 
from 1 ml to 100 l have recently been transiently transfected yielding mg/l range production 
of r-proteins over the period of few days. 
The difference between stable and transient transfection is mainly that transient transfection 
systems do not necessarily require the incorporation of foreign DNA sequence in its own 
nucleus. In spite of lost of the information for production of r-protein when the cell undergoes 
mitosis, the transcription of the transgene and the r-protein expression starts after the foreign 
DNA enters the nucleus. The protein can be then detected in few hours after transfection.  
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Even if transient gene expression (TGE) was originally used for adherent cultures, 
the demand for larger quantities of r-proteins led to the development of large-scale transient 
expressions in suspension cultures (Derouazi et al., 2004). 
 
 
Figure 5. DNA transport by transfection (polyfection): Polycations form soluble complexes with DNA 
and so allow genetic materials to transfer inside cells by endocytosis. From http://www.nano-
lifescience.com/images/dna-transport.gif). 
 
3.7 Poly(ethylenimine) 
Poly(ethylenimine), PEI, is a linear or branched polymer. The branched form of PEI is 
the standard form that is used for gene delivery as it has yielded significantly greater success 
in terms of cell transfection. The basic unit of PEI has a backbone of two carbons followed by 
one nitrogen atom; the branched form of PEI contains 1°, 2° and 3° amines, each with the 
potential to be protonated. This gives PEI the attribute of serving as an effective buffer 
through a wide range of pHs. Because of nitrogen atom appearing as one out of three 
backbone atoms, the benefits of branching and protonability quickly accumulate in relation to 
the overall polymer size. Each PEI nitrogen has its own local environment influencing its 
protonability - the overall buffering capacity over a pH range is then more important than 
obtaining a particular PEI molecule’s pKa (Godbey et al., 1999a). 
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 Figure 6. Structure of linear and branched PEI,  from Godbey et al., 1999a 
Transfection with PEI involves the formation of positively charged nanoparticles containing 
DNA, which enter cells after binding to the negatively charged cell surface and endocytosis 
(Jordan et al., 1996; Seelos, 1997; Brown et al., 2001). Once inside the cell, the cationic PEI 
promotes escape of the DNA from the endosome by binding protons following endosome 
acidification, promoting an influx of chloride ions. This “proton sponge effect” results in 
osmotic swelling of the endosome and subsequent disruption of the endosome which allows 
the DNA to release into the cytoplasm (Lindell, Girard et al., 2004). The extent of this type of 
condensation depends mainly on the PEI:DNA ratio. PEIs with branched structure condense 
to a greater extent than the linear PEIs. The sizes of PEI/DNA complexes have been found to 
be within the range 20-40 nm  using atomic force microscopy (Godbey et al., 1991a). The 
number of plasmids within a PEI/DNA complex remains unknown as of yet, but 
lipopolyamine/DNA complexes have been noted as containing approximately 100 plasmids. 
Much has been published on the formation of the complex and its intracellular transport 
(Boussif, Lezoualc'h et al., 1995; Dunlap, Maggi et al., 1997; Pollard, Remy et al., 1998; 
Choosakoonkriang, Lobo et al., 2003). Many different cell types have been successfully 
transfected with PEI in the presence and absence of serum at many scales of operation 
(Boussif, Lezoualc'h et al., 1995; Godbey et al., 1999a; Godbey et al., 1999b; Durocher et al., 
2002; Derouazi, Girard et al., 2004).  
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3.8 Media 
The cells are cultured in an artificial environment, generally known as growth or culture 
medium. The medium contains an appropriate source of energy for the cells which they can 
easily utilize, and compounds which regulate the cell cycle. A typical medium may or may-
not comprise of serum. In the past, addition of animal serum at concentration of 1-20 % was 
essential for the propagation of mammalian cells. Today, most large-scale cell culture 
processes are performed in serum-free media. These media compositions support excellent 
cell culture performance, in the absence of serum.  
Some of the common sources of serum can be fetal bovine serum, calf serum etc. Both the 
types of media have their own set of advantages and disadvantages. 
The serum contains hormones, nutrients, binding proteins, growth factors and other undefined 
components that generally support the cell line propagation. Major drawback of serum 
dependent cell culture are high costs of high quality sera and complicated and expensive 
subsequent down stream processes (purification). As it is an animal derivative, there is always 
a risk of contamination of r-proteins; the serum composition varies from batch to batch. 
(Girard, Derouazi et al., 2002). Much effort has been made on improving medium 
composition in order to eliminate the presence of serum. 
There are also increasing concerns about animal suffering inflicted during serum collection 
that add an ethical imperative to move away from the use of serum wherever possible. 
(Serum-free media for cell culture) 
 
3.9 Secreted Alkaline Phosphatase (SEAP) 
Alkaline phosphatase, AP (EC 3.1.3.1) is a hydrolase enzyme responsible for removing 
phosphate groups from many types of molecules. As the name proposes, alkaline 
phosphatases are most effective in an alkaline environment. AP is both a membrane bound 
and a free enzyme which occurs in almost all living organisms. Four isoenzymes (placental, 
germ cell, intestinal and tissue nonspecific alkaline phosphatase) have developed during 
evolution and can be found in various tissues, where they have different physiological 
function. 
Placental alkaline phosphatase is the most stable isoenyzme among the four mammalian 
alkaline phosphatase isoenzymes and it only exists naturally in the placenta of higher 
primates. These characteristics make placental alkaline phosphatase the alkaline phosphatase 
of choice to serve as a reporter gene for the analysis of promoter activity and gene expression 
in cell culture or animals. The natural form of placental alkaline phosphates is membrane-
anchored. The recombinant form of placental alkaline phosphatase, secreted alkaline 
phosphatase (SEAP), can be efficiently secreted into tissue culture medium. This unique 
characteristic of SEAP provides the advantage for performing kinetic analysis of gene 
expression over a period of time using a single culture or animal (Secreted Alkaline 
Phosphatase Reporter Gene Assay, Anaspec). 
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4. MATERIALS AND METHODS 
4.1 Chemicals 
Table 1. Chemicals 
DMEM/F-12 medium Cambrex (Lonza) 
BV293s  
Pro293s medium Cambrex (Lonza) 
FCS Cambrex (Lonza) 
HS Cambrex (Lonza) 
Glucose Sigma-Aldrich 
L-glutamine Applichem 
DMSO Sigma-Aldrich 
Trypsin Cambrex (Lonza) 
PEI, PEI-MAX Polysciences 
Plasmid DNA Purification kit Qiagen 
Alkaline phosphatase determination kit BioVendor – Laboratorní medicína 
Phusion HotStart polymerase Finnzymes 
HindIII and XhoI restriction enzymes New England Biolads 
pcDNA5/FRT/TO vector Invitrogen 
• Sterile water, ethanol, isopropanol, NaCl 
• Chemicals used in BV293s preparation are listed in appendix 
 
4.2 Instruments 
• Esco Labculture Class II Biohazard Safety Cabinet 
• Biotek EL 808 spectrophotometer 
• Sigma 6K15 centrifuge 
• Spectrofuge 16M, Labnet centrifuge 
• Lab-Therm, Kühner Switzerland, thermostated orbital shaker 
• Systec V 150 Autoclave 
• Infors HT Labotron orbital shaker with double side adhesive tape  
• Kendra Heracell 240 Heraeus Thermostat 
• PTC-150HB, MJ Research thermocycler 
• Cryostorage Rack System, Taylor-Wharton cryosystem 
• Ultra Fire, Orange Scientific burner 
• Bio Vortex V1, Biosan vortex 
• Qiagen purification columns (and other equipment) 
• Easy-Cast electrophoresis System, Owl Scientific 
• Thermo Fisher Scientific Nanodrop ND-1000 spectrophotometer 
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Tissue Culture OrFlasks T-75cm2 (Orange Scientific), 24 well plates (Orange Scientific), 
Square-shaped glass bottles 100 ml and 250 ml (Schott Duran), Petri dishes, Eppendorf tubes, 
centrifugation tubes (10 ml and 50 ml), cryovials, Bürkner chamber, 22 μm pore filters, 
micropipettes, pipette tips. 
 
4.3 Cell Culture 
4.3.1 Adaptation Phase 
HEK 293F cells (Invitrogen) were thawed to DMEM/F12 medium1 (1:1 mixture of DMEM 
[Dulbecco’s Modified Eagle’s Medium] and Ham's F-12 medium) supplemented with 10% 
fetal calf serum (FCS) into a T-75 bottle. After the cells got attached to the bottle, it was 
crucial to remove the medium containing dimethylsulfoxide (DMSO) which acted as 
a cryoprotectant during the freezing process, but was also toxic to the cells. This medium was 
replaced by fresh DMEM/F12 medium with 10% FCS of the final volume of 20 ml. After 
reaching approximately 90% confluence, the cells were passaged using 0,25% solution of 
trypsin to detach from the surface to fresh DMEM/F12 media with 10% FCS. Later, the cells 
were adapted to BV293s medium”2 with 2% of horse serum (HS) and yet still cultivated in T-
75 bottles as adherent cultures. In following stages, the cells were adapted to suspension 
cultivation in BV293s medium with decreasing ratio of HS (from 2% stepwise to 0%) in 
square-shaped glass bottles on an orbital shaker. 
 
4.3.2 Suspension Cultivation 
The cells were seeded at initial density of 5x105 cells ml-1 into BV293s medium and 
subpassaged every 4-5 days. Cells were cultured in 100 ml of medium when bottles of 
nominal volume of 250 ml were used and bottles of nominal volume of 100 ml were used 
filled with 30 ml of medium. The bottles were fixed to the shaker with double-sided adhesive 
transfer tape and cultivated at 200 rpm. The caps were opened by one quarter of a turn.  
Both adherent and suspension cultures were incubated at 37°C in a 5% CO2 atmosphere with 
95% humidity.  
The cell number was determined using manual counting with a Bürkner chamber; when 
necessary, cell viability was assessed using the trypan blue exclusion method. 
                                                 
1 For the medium composition please refer to Appendix 
2 “BV293s medium“ is DMEM/F12 based medium designed to support suspension cells in the absence of serum. 
Commercial DMEM/F12 medium was supplemented with other components in amounts according to previous 
investigations at the BioVendor’s R&D department, please refer to Appendix. 
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4.3.3 Freezing the Cells 
To keep the stock of cells, it was necessary to freeze the cell cultures. Once the DMSO 
containing medium was replaced with regular DMEM/F12 with 10% FCS, and the cells 
reached 90% confluence, they were frozen. The cells were detached from the surface with 
trypsin. Then the trypsinisation was stopped with equal amount of full medium, the cells were 
centrifuged in order to remove trypsin. Minor part of the cells (usually one eightieth) was 
used for further passaging, while the rest was resuspended in freezing medium (4 ml 
DMEM/F12; 0,5 ml FCS and 0,5 ml DMSO) and the aliquots of 1 ml were pipetted to 1,5 ml 
cryovials. Then the tubes were wrapped in gauze and aluminum foil and placed to -80°C for 
few days. Then the tubes were placed into cryogenic system containing liquid nitrogen.  
 
4.4 Plasmid DNA 
4.4.1 Preparation  
 
Figure 7. Scheme of pcDNA5/FRT/TO plasmid (Invitrogen). 
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Plasmid pcDNA5/SEAP was constructed by amplifying SEAP PCR product by Phusion 
HotStart polymerase from cDNA clone (MGC: 104591, IMAGE: 30330997) with the forward 
and reverse primers: 
5’- CGTAAAGCTTGCCACCATGGTGCTGCTGCTGCTGCTGCTG -3’ (the sequence in 
bold is a HindIII restriction site) and  
5’-GCATCTCGAGTCAACCCGGGTGCGCGGCGTCG -3’ (the sequence in bold is an 
XhoI restriction site), both designed by Petr Orság. The PCR product was digested with 
HindIII and XhoI restriction enzymes and cloned into pcDNA5/FRT/TO vector that had been 
digested with the same two restriction enzymes. 
E. coli cells were transformed with this plasmid, and grown on a LB (10 g.l-1 tryptone, 5 g.l-1 
yeast extract and 10 g.l-1 NaCl) agar plate containing ampicilin. Colonies were picked and 
screened for positive clones by electrophoresis. 
Generated plasmid was verified by sequencing (at MWG Biotech, Germany). 
 
4.4.2 Purification 
Plasmid DNA was purified on Qiagen column, according to the protocol provided by 
the manufacturer. 
These plasmid purification protocols are based on a modified alkaline lysis procedure, 
followed by binding of plasmid DNA to an anion-exchange resin under appropriate low-salt 
and pH conditions. RNA, proteins, dyes, and low-molecular-weight impurities are removed 
by a medium-salt wash. Plasmid DNA is eluted in a high-salt buffer and then concentrated 
and desalted by isopropanol precipitation. 
1. A single colony was picked form a freshly streaked selective plate and a starter culture 
of 2 ml LB medium containing ampicilin was inoculated. Then it was incubated 
overnight at 37°C with vigorous shaking (approx. 300 rpm) 
2. 200 μl of starter culture was diluted in 100 ml of selective LB medium. It was grown 
overnight at 37°C with vigorous shaking (300 rpm) 
3. The bacterial cells were harvested by centrifugation at 6000 x g for 15 minutes at 4°C. 
It was possible to stop the protocol at this point by freezing the cell pellets at -20°C. 
4. The bacterial pellet was resuspended in 10 ml of Buffer P13 (contains RNase A). The 
bacteria were resuspended completely by pipetting up and down until no cell clumps 
remained. 
                                                 
3 For the composition of Qiagen buffers, please refer to Appendix 
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5. 10 ml of Buffer P2 was added; the mixture was 
mixed thoroughly by inverting sealed tube few 
times, and incubated at room temperature for 
5 minutes. 
6. 10 ml of chilled Buffer P3 was added and 
mixed immediately by inverting the tube few 
times. After addition of Buffer P3, a fluffy 
white material was formed containing genomic 
DNA, proteins and cell debris. 
7. The mixture was centrifuged at 10 000 x g for 
15 minutes at 4°C in order to remove 
precipitated impurities.  
8. The lysate was cleared by filtration using 
a cartridge as the suspended material could 
clog the tip and reduce or eliminate gravity 
flow afterwards. 
9. The tip was equilibrated by applying 10 ml 
Buffer QBT and the column was allowed to 
empty by gravity flow.  
10. The supernatant from step 8 was applied to 
the tip and allowed to enter the resin by gravity 
flow. 
11. The tip was washed with 2 x 30 ml Buffer QC.  
12. The DNA was eluted with 15 ml of QF buffer. 
It was possible to stop the protocol at this point 
by storing the eluate at 4°C overnight.  
13. The DNA was precipitated by adding 10,5 ml 
(0,7 volume) room-temperature isopropanol to 
the eluted DNA. It was mixed and centrifuged 
immediately at 5 000 x g for 60 min at 4°C. 
The supernatant was decanted carefully. 
14. The DNA pellet was washed with 5 ml of 
room-temperature 70% ethanol, and 
centrifuged at 15 000 x g for 10 min at 4°C.  
The supernatant was decanted carefully 
without disturbing the pellet. 
15. The pellet was air-dried and the DNA was 
redissolved in appropriate volume of 
TE buffer, pH 8,0. 
Plasmid DNA concentration and purity represented by 
the ratio of absorbance at 260 and 280 nm (A260/280 
values) were determined spectrophotometricaly and 
then the DNA was appropriately diluted in way to get 
1 mg. ml-1 solution. Then this solution was sterilely 
Figure 8. Plasmid DNA purification 
steps. (Qiagen) 
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filtrated, divided into number of 50 μl aliquots and kept at -20°C. Pure DNA (without protein 
or RNA) will have A260/280 of 1,85. RNA will have A260/280 ratio of 2,0. 
 
4.5 Transfection 
4.5.1 Transfection Agents 
Two different transfection agents were used: PEI (Linear polyethyleneimine with molecular 
weight of 25 000 Da) and PEI MAX (High potency linear polyethyleneimine with molecular 
weight of 40 000 Da,), in order to compare their transfection efficiencies and toxicity to cells. 
In both cases, the solutions were prepared in water at a final concentration of 1 mg.ml-1, 
the pH was set to 8,0; the solutions were sterilized by filtration on 0,22 μl pore filter, divided 
into number of 1 ml aliquots and stored at -20°C. 
 
4.5.2 Transfection Process 
One day prior to transfection, the cells were centrifuged (5 minutes at 200 x g), 
the supernatant was removed and the cells were resuspended in 100 ml of fresh BV293s 
medium. The cell density was intended to remain the same as before the centrifugation. 
The cells were then cultivated over night under conditions described above.  
 
4.5.2.1 Transfection of cells in 24 well plate 
On the day of transfection, the cell were counted and a certain volume of medium and cells 
was taken out, centrifuged, and resuspended in 12 ml of fresh BV293s medium and seeded 
into 24 well plate(s) in a way that each well contained 0,5 ml of medium and 106 cells 
(the initial cell density was then 2x106 cells.ml-1). 
The ratios of DNA:transfection agent were varied among experiments in order to find 
an optimal ratio for the highest expression. Eppendorf tubes with solution of DNA or 
transfection agent in sterile NaCl (c = 150 mmol.l-1) solution were prepared. For one 24-well 
plate, 12 tubes containing 2,75 μl of DNA solution and 55 μl of NaCl were prepared; and 
12 tubes with transfection agent solution in NaCl at various concentrations ranging from 
2,75 μl of agent and 55 μl of NaCl to 33 μl of agent and 24,75 μl of NaCl, always at final 
volume of 57,75 μl were prepared (both calculating with 10% surplus of volume to avoid 
possible lack of solution caused by manipulations, mainly by pipetting). 
Then the tubes were vortexed, the appropriate DNA and agent solutions were mixed, 
vortexed, left still for 10 minutes and then 50 μl of the final solution was added to one well 
(so one mixture was used for transfection of two wells: all the experiments were done in 
duplicates). 
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Then the plate was placed on an orbital shaker and the cells were cultivated under conditions 
described above.  
At 4 hours post-transfection, 0,5 ml of BV293s medium was added to each well. 
On the day 3 and 6 post-transfection, 30 μl of medium was taken out from every well and 
either stored at -20°C or immediately used for measurement of SEAP expression levels. 
 
4.5.2.2 Transfection of cells in square-shaped bottles 
On the day of transfection, the cells were counted and a certain volume of medium and cells 
was taken out, centrifuged, and resuspended in 75 ml of fresh BV293s medium and seeded 
into 6 square-shaped bottles in a way that each bottle contained 12,5 ml of medium and 
25.106 cells (the initial cell density was then 2x106 cells.ml-1). 
The ratios of DNA:transfection agent were varied in order to find an optimal ratio for the 
highest expression. Eppendorf tubes with solution of DNA or transfection agent in sterile 
NaCl (c = 150 mmol.l-1) solution were prepared. 
For transfection of each bottle, 1 Eppendorf tube with solution of DNA in NaCl (33,875 μl of 
DNA solution and 687,5 μl of 150 mmol.l-1 NaCl) and one tube with PEI solution in NaCl at 
amounts corresponding to particular DNA:PEI ratio (final volume of 721,875 μl) were 
prepared (both calculating with 10% surplus of volume to avoid possible lack of solution 
caused by manipulations, mainly by pipetting). 
Then the tubes were vortexed, the appropriate DNA and PEI solutions were mixed, vortexed, 
left still for 10 minutes and then 1250 μl of final solution was added to each bottle.  
Then the bottles were placed on an orbital shaker and the cells were cultivated under 
conditions described above.  
At 4 hours post-transfection, 12,5 ml of BV293s medium was added to each bottle. 
On the day 3 and 6 post-transfection, 30 μl of medium was taken out from every well and 
either stored at -20°C or immediately used for measurement of SEAP expression levels. 
 
4.6 Reporter Protein Quantification 
The SEAP expression was measured according to (Durocher et al., 2000). The determination 
of alkaline phosphatase was determined using “Alkaline Phosphatase” kit. The reaction agent 
(substrate) was prepared according to the product instructions (BioVendor: Alkalická 
fosfatáza): 40 ml of R1 (0,90 mol.l-1 2-amino-2-methyl-1-propanol, ph 10,4; 1,6 mmol.l-1 
magnesium acetate; 0,4 mmol.l-1 zinc sulphate; 2,0 mmol.l-1 HEDTA) solution was mixed 
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with 10 ml of R2 solution (16,0 mmol.l-1 nitrophenylphosphate). This solution was kept at 
4°C and it is reported to be stable for one month. 
Prior to measurement, the solution was prewarmed to 37°C. 
4 μl of the sample were transferred to a new 96-well plate and mixed with 200 μl of the SEAP 
assay solution. If necessary, the sample was appropriately diluted in order to obtain 
absorbance values no higher than 2,5 as the absorbances higher than 2,5 does not show linear 
behavior anymore (SEAP standard-zpráva). After one minute incubation, the absorbances 
were measured at 405 nm at time 0, 1, 2, and 3 minutes. The data were gathered and assessed 
using Gen5 software from BioTek.  
The final concentrations of exprimed protein were calculated from a calibration curve 
obtained from the measurement of absorbance change of the standard (ProspecBio, ENZ-333) 
solution diluted 1:2000, 1:4000, 1:6000 and 1:8000 in buffer (50mM Tris-Acetate, pH 7,5, 
1mM EDTA and 20% Glycerol) corresponding to enzyme concentration of 5,76; 2,88; 1,92 
and 1,44 mg.l-1 resp.  
Even though the coefficient of determination (R2) value of the regression of the calibration 
curve was always higher than 0,997 (0 indicating no linear relation between Y and X, and 
1 indicating a perfect linear relation between Y and X); the actual coefficients of the 
appropriate regression line varied. For these reasons it was necessary to do measurements 
with the diluted standards simultaneously with the measurement of experiment samples at all 
times. 
 
4.7 Evaluation of Results 
The results have been evaluated using Microsoft Office Excel and R statistical package 
(The R Foundation for Statistical Computing).  
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5. RESULTS 
The purpose of thesis was to optimize the parameters of the actual SEAP production in the 
HEK 293 cells. The crucial factor to be optimized was the DNA:PEI ratio. While DNA 
amount used for transfection of one well on the 24 well plate was the same in all the 
experiments, the PEI amount was varied. Then the process was scaled up. 
 
5.1 Effect of time on SEAP Production 
In the first set of experiments, differences in transfection efficiencies on different days after 
transfection were evaluated in order to find one day when the later transfection efficiencies 
would be analyzed. The SEAP expression was measured at day 3 and day 6 post-transfection. 
It was noticed, that there was no significant difference in SEAP concentrations between these 
two days. Based on these findings, only the SEAP concentrations measured on the day 6 post-
transfection will be analyzed further. 
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5.2 Effect of DNA:PEI Ratio on Transfection Efficiency 
 
Figure 9. The effect of the DNA:PEI ratio on the SEAP expression. 3 independent experiments 
(proceeded in duplicates) were analyzed. Decreasing the DNA:PEI ratio was followed by an increase 
of transfection efficiency (represented by SEAP concentration). Decreasing the DNA:PEI ratio from 
1:4 to 1:6 did not result in further increase of SEAP concentration. The differences in transfection 
efficiencies at ratios 1:4, 1:5 and 1:6 were statistically insignificant (p>0,01). Data were summed up 
in boxplot, where the lower and upper ends of the box mark the 25th and 75th percentiles, the solid 
band indicates the 50th percentile (median), and the whiskers represent the range of values out to 1,5 
times the interquartile range (IQR). Data which lies more than 1,5.IQR lower than the first quartile or 
1,5.IQR higher than the third quartile is considered an outlier-indicated by dots. 
Tukey's multiple comparison of means was used in order to find significant pairwise 
differences between single DNA:PEI ratios. Differences in transfection efficiencies when 
DNA:PEI ratio of 1:4 to 1:6 were used, were found statistically insignificant, while the 
difference between 1:1 and 1:3 were significant. This analysis also confirmed that there were 
significant differences between SEAP concentrations at different DNA:PEI ratios, while the 
expression levels proved to be experiment independent.4 
From these results it was apparent, that the highest level of protein expression was achieved 
when used the higher DNA:PEI ratio of 1:6 (even though the difference between expressions 
at 1:4, 1:5 and 1:6 DNA:PEI ratios proved to be statistically insignificant), and it was possible 
                                                 
4 For statistical evaluation of results, please refer to Appendix. 
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that the optimal ratio was not reached. So the next two experiments were designed to show, if 
the optimal DNA:PEI ratio would be lower than 1:6. 
However, these two independent experiments had to be analyzed separately in order to obtain 
datasets with a normal distribution. This unexpected distribution was caused by different 
expression levels of each experiment. However, the behavior of the system was similar in 
both experiments. In the “A” experiment, the highest expression of 8 mg.l-1 of SEAP was 
achieved at DNA:PEI ratio 1:8 or 1:9; while in the “B” experiment, the highest expression 
was 2 mg.l-1 at ratio of 1:6 or 1:7. Data of the “A” experiment show statistically insignificant 
differences between transfection efficiencies at different DNA:PEI ratios, but it could have 
been caused by the data dispersion at the 1:11 ratio. In the “B” experiment, the differences 
between expressions at different DNA:PEI ratios were found statistically significant (p<0,01). 
 
Figure 10. The effect of the DNA:PEI ratio on the SEAP expression. Evaluation of the “A” experiment 
proceeded in duplicates: It was tested whether the SEAP concentration would increase at 
the DNA:PEI ratios lower than 1:6. Decreasing the DNA:PEI ratio from 1:6 to 1:9 resulted in 
an increase of SEAP concentration, while further ratio decreasing actually caused decrease of 
transfection efficiencies.  
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5.3 Effect of DNA:PEI-MAX Ratio on Transfection Efficiency 
Experiments in this section were performed similarly as described above, the transfection 
agent used was PEI-MAX and the DNA:PEI-MAX ratios were varied from 1:3 to 1:10.  
 
Figure 11. Effect of DNA:PEI-MAX ratio on transfection efficiency. Data represent results of two 
independent experiments, each proceeded in duplicates. Decreasing the DNA:PEI-MAX ratio to 1:6 
was followed by an increase of transfection efficiency (represented by SEAP concentration). Further 
decreasing of the DNA:PEI-MAX ratio led to a decrease of the transfection efficiency.  
The differences between transfection efficiencies at different DNA:PEI-MAX ratios were 
found to be statistically significant (p<0,01). The optimal DNA:PEI-MAX ratio was 1:6 
which was also post hoc confirmed by the Tukey’s test.  
These results would suggest PEI-MAX to be better transfection agent as higher expressions 
were obtained at lower DNA:agent ratio. On the other hand, determination of the optimal 
DNA:PEI ratio was very complicated due to big differences in SEAP concentration among 
single experiments (from milligram to tens of milligrams of SEAP per liter).  
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 Figure 12. PEI and PEI-MAX transfection agent comparison, each bar represents the mean of two 
independent absorbance measurements. These results were gathered from set of two experiments 
performed the same day at the same cells cultured together. Even though the concentration of 
expressed protein is rather low, the comparison of two kinds of transfection agents shows that (even if 
the optimal ratio was not reached for PEI) the efficiencies were comparable. 
When the experiment with PEI and PEI-MAX transfection agents were performed on 
the identically cultivated cells on the same day, the final SEAP concentrations when either 
agents were used, were not statistically significantly different (p>0,01). 
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5.4 Other Experiments  
5.4.1 Effect of Transfection Buffer 
Here, the solution composition was simplified in order to find out whether the process of 
transfection could be shortened somehow. Transfection efficiencies of when both DNA and 
transfection agents were diluted either in 150 mmol.l-1 NaCl (as in all previous experiments), 
or in the same amount of the BV293s medium were compared. The experiment was designed 
only for the PEI transfection agent, as the main goal was to focus on the DNA:PEI ratio 
problem. This experiment proved no statistically significant difference between transfection 
efficiencies when either of these two buffers were used (p>0,01). 
 
Figure 13. Influence of transfection buffer on SEAP concentration. Data were gathered from one 
experiment proceeded in duplicates.  Experiments with NaCl buffer shown in blue, experiment with 
BV293s medium shown in red. The data showed no statistically significant difference between 
experiments (p>0,01). 
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5.4.2 The Cell Density One Day Pre-transfection 
To demonstrate the importance of cell density prior to transfection, transfection efficiencies 
of two cultures of cells having different cell densities on the first day pre-transfection were 
compared. The cells were cultured separately under identical conditions. One day prior 
to the transfection, the cells were centrifuged and seeded into fresh media at two 
different cell densities. Either the cell density was kept the same as prior to centrifugation 
(2,5x106 cells.ml-1), or the cells were seeded at 1x106 cells.ml-1, resp. 
 
*
Figure 14. Effect of the one day pre-transfection cell density on the final SEAP expression. One day 
prior to transfection the cells were centrifuged and seeded into fresh media: either the cell density was 
kept the same - 2,5x106 cells.m-1l ( blue) or the cells were seeded at density of 1x106 cells.ml-1 (red). 
The cells with higher initial density showed higher expression levels.  
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5.4.3 Transfection in Square-shaped Bottles 
The goal of this experiment was to verify whether it was possible to scale-up the present 
expression system. At different volumes, different behavior of the system has to be expected. 
The transfection took place in glass square-shaped bottles of nominal volume of 100 ml filled 
with 25 ml of medium. The amounts of plasmid DNA, PEI and NaCl had to be elevated 25-
fold compared to the transfection in one well of 24-well plate. As the cost of the chemicals 
was significant, only 3 DNA:PEI ratios were tested. Every experiment was proceeded in 
duplicates.  
 
Figure 15. Comparison of SEAP expression at different DNA:PEI ratios and at different scale: in 24 
well plate and in square-shaped bottles of nominal volume of 100 ml filled to 25 ml – the data from 
day 6 and day 10 post-transfection are shown in the case of transfection of cells in bottles. Every 
experiment was proceeded in duplicates.  
Also the data from the day 10 post-transfection are shown in the case of the transfection in 
square-shaped bottles as I believe, that I measured the actual SEAP concentration (the effect 
of the sample getting more concentrated because of water evaporation could be omitted, and 
the take-out of 30 μl out of 25 ml should not significantly influence the cell concentration and 
other conditions). 
Ratios 1:6, 1:7 and 1:8 resp. were tested. As mentioned above, the expression levels were 
found to be highly dependent on the cell state and the expression levels varied from 
experiment to experiment. For these reasons, transfection at 24 well plate and bottles was 
designed in order to find out, whether the transfection efficiency was really different at 
different scale. The data from different scale were found statistically significantly different 
(p<0,01), while the expressions at different ratios did not vary much (p>0,01). 
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6. DISCUSSION 
In the first experiments, the goal was to describe the transfection efficiency at different 
DNA:PEI ratios. Previous result at this lab under comparable conditions showed that the ideal 
SEAP expression at the 24 well plate scale was 15 mg.l-1 at ratio 1:3. For this reason, in 
the first set of experiments, only ratios from 1:1 to 1:6 were applied.  Higher DNA:PEI ratios 
in following experiments were tested in order to confirm an apparent trend of increasing 
transfection efficiency with decreasing DNA:PEI ratio. It turned out that the optimal ratio was 
at least in some cases higher than 1:6. The results from these experiments would suggest 
the DNA:PEI  ratios ranging from 1:6 to 1:9.  
 
6.1 Comparison of Transfection Agents 
In this part, data obtained from different transfection agents will be discussed. Both PEI and 
PEI-MAX were purchased from the same company (Polysciences). It was reported that 
removal of the residual N-acyl moieties from commercial linear 25-kDa PEI enhanced its 
plasmid DNA delivery efficiency 21 times in vitro (Thomas et al., 2005). It was also reported 
to deliver the DNA with the same efficiency, but at lower concentration. These improvements 
are caused by an increase in the number of protonable nitrogens, which most likely results in 
a tighter condensation of plasmid DNA and a better endosomal escape of the PEI/DNA 
complexes. 
It was found that the highest expression was obtained at ratio 1:7 when PEI transfection agent 
was used: the concentration of exprimed protein was 25 mg.l-1; while when PEI-MAX was 
used, the highest expression of 24 mg.l-1 was obtained at 1:6 ratio in these experiments.  
Comparable experiments at 12 well plate scale yielding expression of 20 mg.l-1 of IgG at 
DNA:PEI ratio of 1:3 in RPMI 1640 medium were reported, however the optimal DNA:PEI 
ratio in a different medium (Ex-Cell 293 CDM) was 1:11 (Muller, 2005). 
It remains to compare these transfection agents at higher scale which would enable 
the determination of the optimal DNA:PEI ratio and the most efficient transfection agent for 
the production environment. 
Another issue to discuss is whether the actual optimal ratio would be really applied when 
the real production of protein will be expected. Increasing the transfection agent amount to 
the optimal ratio increases the production, but there is a question, if the price of added n-th 
part would cause appropriate increase in production-mainly economically.  
 
6.2 Scaling up 
I have succeeded in scaling the transfection from 24 well plates up to 25 ml volume in glass 
square-shaped bottles. According to the previous observations, I have tested the transfection 
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efficiencies at the DNA:PEI ratios of 1:6, 1:7 and 1:8 resp. At different scale, different 
behavior of the system has to be expected.  
The highest expression achieved in 25 ml of medium in glass square-shaped bottles of 
the nominal volume of 100 ml was 32 mg.l-1 on the day 6 post-transfection and 45 mg.l-1 on 
the day 10 post-transfection. Until then, the highest SEAP concentration at 24 well plate scale 
was 25 mg.l-1.  
There was also an experiment on 24 well plate at that same time in order to clarify, whether 
the results were mainly dependent on the scale, or whether the cells were in condition that 
allowed higher expression. Higher yields were expected as the mixing and aeration is 
significantly better in the square-shaped bottles than in the plate. But as noted before, the 
main factor influencing the expression up to now was the state of the cells. 
Unfortunately it is not evident, whether these ratios were optimal and whether rising or 
lowering of PEI amount would increase or decrease the final SEAP expression. However, 
I am happy to see that it was not only possible to scale up, also higher expression levels were 
achieved. 
It was reported that this system proved to be scalable from 1 ml in microtiter plates, 50 ml 
centrifuge tubes, 1-liter round and square glass bottles to 3-liter bioreactors (Muller, 2005).  
Currently, the most widely used DNA delivery agent for large-scale TGE appears to be PEI. 
Transfection of 293 HEK cells with PEIs in 1-liter stirred tank reactor yielding 10 mg.l-1 of 
SEAP was reported (Pham et al., 2005), while transfections in 1-liter agitated square-shaped 
bottles reported IgG yields up to 80 mg.l-1 (Muller, 2005). 
 
6.3 Other Improvements 
Besides the DNA:agent ratio, the system was also improved at few other issues. 
An experiment showing the possibility of diluting the DNA and the transfection agent in 
the culture medium instead of in the 150 mmol.l-1 NaCl solution was designed. The results 
showed that it was not necessary to use the NaCl solution and the process could be shortened 
and simplified by using the medium. 
It was possible to find the optimal DNA:transfection agent, however, the expressions 
achieved varied a lot. To determine if the cell density prior to transfection played an important 
role in the transfection efficiency, the cells were cultured separately under identical 
conditions. One day pre-transfection, the cells were seeded into fresh media and the cell 
density was either kept the same (2,5x106 cells.ml-1), or the cells were seeded at 106 cells.ml-1. 
The results showed that higher expressions were obtained when the cells were kept at their 
previous (high) density. Similar results were observed in case of calfection of HEK 293 cells 
previously (Muller, 2005). 
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7. CONCLUSIONS 
There is a great potential in production of recombinant proteins in mammalian cells. Even 
though the transient expression does not deliver big amounts or r-proteins, it is sufficient for 
the research purposes and for preclinical studies. This method has also proved to shorten 
the time of production phase to few days. 
In this thesis, a process of 293 HEK suspension adapted cells transfection with 
polyethyleneimines was optimized at some of the major factors, while there are still other 
ones that remain to be investigated. First, the cells were successfully adapted to suspension 
cultivation in serum free medium. Then plasmid DNA containing the SEAP expression 
sequence based on pcDNA5/FRT/TO plasmid was designed; PEI and PEI-MAX 
polyethyleneimines at wide range of DNA:agent ratios were used for transfection in order to 
find the optimal one. It was noticed that it was convenient to measure the SEAP concentration 
on the day 6 after transfection. The optimal ratio of DNA:PEI and DNA:PEI-MAX were 
determined and also transfection efficiencies when either of these transfection agents were 
used, were compared. Apart from that, the system behavior was tested after having slightly 
modified the transfection protocol and it turned out that BV293s medium could be used as 
a buffer instead of the NaCl solution. Finally, the process was scaled up from 24 well plates to 
square-shaped bottles containing 25 ml of medium. The maximum expression achieved was 
25 mg.l-1 of SEAP (calculated from comparison with commercial AP standard efficiency) in 
24 well plates and 45 mg.l-1 in the case of transfection in square-shaped bottles. According to 
the fact, that actually only the DNA:agent ratio factor was optimized, there is a great potential 
of increasing the expression after having optimized other issues. 
I also have to mention  that the cultivation of mammalian cells was challenging – first of all 
there was a strict requirement for sterile materials and chemicals which came into contact 
with the cells: during first two months, I was facing few contamination of the cells caused 
probably by lack of experience with working in aseptic conditions. The cultivation is also 
a long-term process in which one mistake may ruin all the present work. The time span 
starting from thawing the cells, through numerous subpassages, adaptation to suspension 
cultivation and serum free medium, to the transfection itself is approximately one month.  
 39
8. PERSPECTIVES 
After finding the optimal DNA:transfection agent ratio, and scaling up from 24 well plates to 
small square shaped bottles, I found out that this present system had the potential for 
increasing the SEAP yield significantly if I have had optimized other issues. 
 
• To show the scalability of the system starting at 100 ml square-shaped bottles to 
bioreactor scale. The system behavior is expected to be slightly different at higher 
scale, but the main characteristic should remain the same, if the system works.  
 
• It would also be useful to verify the actual necessity of some time-dependent steps, as 
the one day pre-transfection cells seeding into fresh media at particular densities, or 
moving the cultivation to thermostat without controlled CO2 atmosphere. 
 
• As it turned out, the actual protein expression was dependent mainly on the state of 
the cells, it would be beneficial to monitor the cell cultivation conditions as cell 
density, lactate or glucose concentration in the medium to find out what does influence 
the protein expression afterwards.  
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10. ABBREVIATIONS 
AP  alkaline phosphatase 
BV293s medium designed to support 293 HEK cells in suspension cultivation 
(BioVendor) 
CaPi  calcium phosphate precipitation 
cDNA  complementary deoxyribonucleic acid  
DMEM Dulbecco’s  Modified Eagle’s Medium 
DMSO dodecylmethylsulphate 
FCS  fetal calf serum 
HEK  human embryonic kidney 
HS  horse serum 
LB  Luria Bertani medium 
PEI  poly(ethylenimine) 
PCR  polymerase chain reaction 
PLAP  placental alkaline phosphatase 
r-protein recombinant protein 
SEAP  secreted alkaline phosphatase 
TGE  transient gene expression 
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11. APPENDICES 
11.1 BV293s Medium Composition 
Table 2.  BV293s medium composition  
Content Concentration
DMEM/F12 (Lonza BE12-719F) 1 liter 
HEPES (Research Organics 6017H) 3,58 g.l-1 
D-Phantothenic acid hemicalcium salt (Sigma P5155) 4 mg.l-1 
Ethanolamin (Sigma-Aldrich E0135) 3 μg.l-1 
Human transferin isolated from plasma (ProSpec-Tany TechnoGene LTD 
CYT-270) 5,0 g.l
-1
 
Recombinant human insulin (ProSpec-Tany TechnoGene LTD PRO325A) 5,0 g.l-1 
CD Lipid concentrate (Gibco 11905-031) 1 mg.l-1 
Pluronic F68 (Sigma P1300) 1 g.l-1 
Difco TM Select Soytone (Becton&Dickison 212488)  1 g.l-1 
Bacto TM Yeastolate (Becton&Dickison 255772) 2 g.l-1 
D-(+)-Glukose (Sigma G6152) 6 g.l-1 
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11.2 DMEM/F-12 Medium Composition 
Table 3. DMEM/F-12medium composition 
Content Concentration 
CaCl2 (anhyd.) 116,00 mg.l-1 
Fe(NO3)3•9H20 0,05 mg.l-1 
FeSO4•7H20 0,42 mg.l-1 
KCl 311,83 mg.l-1 
MgCl2•6H20 61,00 mg.l-1 
MgSO4•7H20 100,00 mg.l-1 
NaCl 6,99950 mg.l-1 
NaHCO3 1,20000 g.l-1 
Na2H2P04•7H20 134,00 mg.l-1 
NaH2P04•H20 62,50 mg.l-1 
ZnSO4•7H20 0,43 mg.l-1 
Glucose 3,15100 g.l-1 
HEPES 3,57450 g.l-1 
Hypoxanthine 2,04 mg.l-1 
Linoleic Acid 0,04 mg.l-1 
Lipoic Acid 0,10 mg.l-1 
Phenol Red•Na 8,00 mg.l-1 
Putrescine•2HCl 0,08 mg.l-1 
Sodium Pyruvate 110,00 mg.l-1 
Thymidine 0,36 mg.l-1 
L-Alanine 4,46 mg.l-1 
L-Arginine•HCl 147,35 mg.l-1 
L-Asparagine•H20 7,50 mg.l-1 
L-Aspartic Acid 6,66 mg.l-1 
L-Cysteine•HCl•H20 17,56 mg.l-1 
L-Cystine 24,00 mg.l-1 
L-Glutamic Acid 7,36 mg.l-1 
L-Glutamine 365,10 mg.l-1 
L-Alanyl-L-Glutamine (UltraGlutamine 1) 868,00 mg.l-1 
Glycine 18,76 mg.l-1 
L-Histidine•HCl•H20 31,48 mg.l-1 
L-Isoleucine 54,37 mg.l-1 
L-Leucine 58,96 mg.l-1 
L-Lysine•HCl 91,37 mg.l-1 
L-Methionine 17,24 mg.l-1 
L-Phenylalanine 35,48 mg.l-1 
L-Proline 17,27 mg.l-1 
L-Serine 26,26 mg.l-1 
L-Threonine 53,56 mg.l-1 
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11.3 Qiagen Buffers Composition 
Table 4. Qiagen Buffers Composition 
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11.4 Statistics 
11.4.1 Program R : 
R version 2.6.2 (2008-02-08) © The R Foundation for Statistical Computing 
The Rcmdr package (a platform-independent basic-statistics GUI (graphical user interface) 
for R, based on the tcltk package). 
Version 1.3-12 (2008-1-24) 
URL:  http://www.r-project.org, http://socserv.socsci.mcmaster.ca/jfox/Misc/Rcmdr/ 
 
11.4.2 Effect of DNA:PEI Ratio on Transfection Efficiency 
11.4.2.1 DNA:PEI ratios 1:1 to 1:6 
summary(fm1 <- aov(concentration ~ ratio*experiment, data=pei16)) 
Df  Sum Sq Mean Sq F value Pr(>F) 
Ratio   5  33.871 6.774  9.1311  0.0001836  *** 
Experiment  2 0.832  0.416  0.5609  0.5803577  
ratio:experiment 10  18.289 1.829  2.4652  0.0459975  *  
Residuals  18  13.354 0.742 
*** show that the ratio is statistically significant; * refers to the dependency between ratio 
and experiment, which means that the concentration at comparable ratios were not 
comparable at different experiments.  
TukeyHSD(fm1, "ratio", ordered = TRUE) 
Tukey multiple comparisons of means  
95% family-wise confidence level 
factor levels have been ordered 
 
Fit: aov(formula = concentration ~ ratio * experiment, data = pei16) 
$ratio 
Diff   lwr   upr  p adj 
1:2-1:1  0.24257732  -1.3378262  1.822981  0.9960208 
1:3-1:1  0.97987294  -0.6005306  2.560277  0.3952232 
1:4-1:1  1.95013698    0.3697334  3.530541  0.0108832 
1:6-1:1 2.34847234    0.7680688  3.928876  0.0019982 
1:5-1:1  2.40235595    0.8219524  3.982760  0.0015893 
1:3-1:2  0.73729563  -0.8431079  2.317699  0.6788376 
1:4-1:2  1.70755966    0.1271561  3.287963  0.0299239 
1:6-1:2  2.10589503    0.5254915  3.686299  0.0056177 
1:5-1:2  2.15977863    0.5793751  3.740182  0.0044651 
1:4-1:3  0.97026404  -0.6101395  2.550668  0.4054740 
1:6-1:3  1.36859940  -0.2118042  2.949003  0.1126373 
1:5-1:3  1.42248301  -0.1579206  3.002887  0.0921895 
1:6-1:4  0.39833536  -1.1820682  1.978739  0.9636526 
1:5-1:4  0.45221897  -1.1281846  2.032623  0.9390653 
1:5-1:6  0.05388361  -1.5265200  1.634287  0.9999975 
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 Figure 16. Graphical interpretation of Tukey’s comparison of means of SEAP concentrations at first 
set of experiments. 
11.4.2.2 DNA:PEI Ratios 1:6 to 1:13-the “A” Experiment 
summary(fm1 <- aov(concentration ~ ratio, data=pei2a66)) 
            Df  Sum Sq Mean Sq F value Pr(>F) 
ratio        7 17.5143  2.5020  1.2092 0.3944 
Residuals    8 16.5534  2.0692 
 
TukeyHSD(fm1, "ratio", ordered = TRUE) 
ratio     diff       lwr      upr     p adj 
1:10-1:06 0.36597915 -5.326161 6.058119 0.9999921 
1:07-1:06 0.65559932 -5.036541 6.347739 0.9996109 
1:13-1:06 1.36014523 -4.331995 7.052285 0.9710943 
1:12-1:06 1.87483612 -3.817304 7.566976 0.8750353 
1:11-1:06 1.95881200 -3.733328 7.650952 0.8518256 
1:09-1:06 2.76064623 -2.931494 8.452786 0.5739359 
1:08-1:06 3.09654975 -2.595590 8.788690 0.4572640 
1:07-1:10 0.28962017 -5.402520 5.981760 0.9999984 
1:13-1:10 0.99416608 -4.697974 6.686306 0.9948562 
1:12-1:10 1.50885697 -4.183283 7.200997 0.9517647 
1:11-1:10 1.59283285 -4.099307 7.284973 0.9378590 
1:09-1:10 2.39466708 -3.297473 8.086807 0.7077034 
1:08-1:10 2.73057061 -2.961569 8.422710 0.5848518 
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1:13-1:07 0.70454592 -4.987594 6.396686 0.9993818 
1:12-1:07 1.21923680 -4.472903 6.911377 0.9837236 
1:11-1:07 1.30321269 -4.388927 6.995353 0.9768153 
1:09-1:07 2.10504691 -3.587093 7.797187 0.8072565 
1:08-1:07 2.44095044 -3.251189 8.133090 0.6909369 
1:12-1:13 0.51469089 -5.177449 6.206831 0.9999207 
1:11-1:13 0.59866677 -5.093473 6.290807 0.9997846 
1:09-1:13 1.40050100 -4.291639 7.092641 0.9664937 
1:08-1:13 1.73640452 -3.955735 7.428544 0.9089265 
1:11-1:12 0.08397588 -5.608164 5.776116 1.0000000 
1:09-1:12 0.88581011 -4.806330 6.577950 0.9974184 
1:08-1:12 1.22171363 -4.470426 6.913854 0.9835443 
1:09-1:11 0.80183423 -4.890306 6.493974 0.9986013 
1:08-1:11 1.13773775 -4.554402 6.829878 0.9888659 
1:08-1:09 0.33590353 -5.356236 6.028043 0.9999956 
 
 
Figure 17.  Graphical interpretation of Tukey’s comparison of means of SEAP concentrations: 
the “A” experiment 
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11.4.2.3 DNA:PEI Ratios 1:6 to 1:13 – the “B” Experiment 
 
Figure 18. Effect of different DNA:PEI ratio on SEAP concentration. Decreasing the DNA:PEI ratio 
from 1:7 to 1:13 resulted in decrease of transfection efficiency. Data corresponding to the DNA:PEI 
ratio of 1:12 should be omitted from the analysis as they were caused by some random error.  
 
summary(fm1 <- aov(concentration ~ ratio, data=pei2b66)) 
            Df Sum Sq Mean Sq F value    Pr(>F)     
ratio        7 4.0965  0.5852  53.676 4.250e-06 *** 
Residuals    8 0.0872  0.0109   
 
TukeyHSD(fm1, "ratio", ordered = TRUE) 
Ratio      diff         lwr       upr     p adj 
1:11-1:13 0.12528008 -0.28790414 0.5384643 0.9112641 
1:10-1:13 0.33825621 -0.07492800 0.7514404 0.1250692 
1:09-1:13 0.76921969  0.35603547 1.1824039 0.0011506 
1:08-1:13 0.90452217  0.49133795 1.3177064 0.0003677 
1:06-1:13 1.19973318  0.78654896 1.6129174 0.0000459 
1:07-1:13 1.25297950  0.83979529 1.6661637 0.0000330 
1:12-1:13 1.41817050  1.00498628 1.8313547 0.0000130 
1:10-1:11 0.21297613 -0.20020808 0.6261604 0.5122871 
1:09-1:11 0.64393961  0.23075539 1.0571238 0.0037888 
1:08-1:11 0.77924209  0.36605788 1.1924263 0.0010522 
1:06-1:11 1.07445310  0.66126888 1.4876373 0.0001047 
1:07-1:11 1.12769942  0.71451521 1.5408836 0.0000730 
1:12-1:11 1.29289042  0.87970620 1.7060746 0.0000261 
1:09-1:10 0.43096347  0.01777925 0.8441477 0.0403335 
1:08-1:10 0.56626596  0.15308174 0.9794502 0.0085411 
1:06-1:10 0.86147696  0.44829275 1.2746612 0.0005207 
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1:07-1:10 0.91472329  0.50153907 1.3279075 0.0003393 
1:12-1:10 1.07991428  0.66673007 1.4930985 0.0001008 
1:08-1:09 0.13530249 -0.27788173 0.5484867 0.8778994 
1:06-1:09 0.43051349  0.01732927 0.8436977 0.0405524 
1:07-1:09 0.48375982  0.07057560 0.8969440 0.0215913 
1:12-1:09 0.64895081  0.23576659 1.0621350 0.0036025 
1:06-1:08 0.29521101 -0.11797321 0.7083952 0.2102247 
1:07-1:08 0.34845733 -0.06472689 0.7616415 0.1103883 
1:12-1:08 0.51364832  0.10046411 0.9268325 0.0153165 
1:07-1:06 0.05324633 -0.35993789 0.4664305 0.9992008 
1:12-1:06 0.21843732 -0.19474690 0.6316215 0.4864276 
1:12-1:07 0.16519099 -0.24799322 0.5783752 0.7499523 
 
 
Figure 19. Graphical interpretation of Tukey’s comparison of means of SEAP concentrations: 
the “B” experiment. 
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11.4.3 Effect of DNA:PEI-MAX Ratio on Transfection Efficiency 
summary(fm1 <- aov(concentration ~ experiment*ratio, data=maxAB6)) 
                 Df Sum Sq Mean Sq F value   Pr(>F)    
experiment        1 196.98  196.98 14.5463 0.001527 ** 
ratio             7 540.68   77.24  5.7039 0.001919 ** 
experiment:ratio  7 269.30   38.47  2.8409 0.039666 *  
Residuals        16 216.67   13.54 
 
TukeyHSD(fm1, "ratio", ordered = TRUE) 
Ratio        diff        lwr       upr     p adj 
1:04-1:03  0.56283432 -8.4459919  9.571661 0.9999982 
1:09-1:03  5.09418726 -3.9146390 14.103014 0.5353186 
1:10-1:03  6.10073597 -2.9080903 15.109562 0.3290919 
1:08-1:03  6.11800057 -2.8908257 15.126827 0.3260297 
1:07-1:03  6.62704540 -2.3817808 15.635872 0.2443033 
1:05-1:03  7.13524939 -1.8735768 16.144076 0.1791356 
1:06-1:03 14.22507677  5.2162505 23.233903 0.0010466 
1:09-1:04  4.53135294 -4.4774733 13.540179 0.6633539 
1:10-1:04  5.53790165 -3.4709246 14.546728 0.4385020 
1:08-1:04  5.55516624 -3.4536600 14.563992 0.4348935 
1:07-1:04  6.06421107 -2.9446152 15.073037 0.3356313 
1:05-1:04  6.57241507 -2.4364112 15.581241 0.2522744 
1:06-1:04 13.66224245  4.6534162 22.671069 0.0015798 
1:10-1:09  1.00654871 -8.0022775 10.015375 0.9999068 
1:08-1:09  1.02381330 -7.9850129 10.032640 0.9998956 
1:07-1:09  1.53285813 -7.4759681 10.541684 0.9985473 
1:05-1:09  2.04106213 -6.9677641 11.049888 0.9916640 
1:06-1:09  9.13088950  0.1220633 18.139716 0.0457866 
1:08-1:10  0.01726459 -8.9915616  9.026091 1.0000000 
1:07-1:10  0.52630942 -8.4825168  9.535136 0.9999989 
1:05-1:10  1.03451342 -7.9743128 10.043340 0.9998881 
1:06-1:10  8.12434080 -0.8844854 17.133167 0.0932288 
1:07-1:08  0.50904483 -8.4997814  9.517871 0.9999991 
1:05-1:08  1.01724883 -7.9915774 10.026075 0.9999000 
1:06-1:08  8.10707620 -0.9017500 17.115902 0.0943402 
1:05-1:07  0.50820400 -8.5006222  9.517030 0.9999991 
1:06-1:07  7.59803137 -1.4107949 16.606858 0.1329032 
1:06-1:05  7.08982738 -1.9189989 16.098654 0.1843198 
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 Figure 20. Graphical interpretation of Tukey’s comparison of means of SEAP concentrations when 
different ratios of DNA:PEI-MAX were used. 
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11.4.4 Transfection Agents Comparison 
Multiway anova: 
Response: concentration 
             Sum Sq Df  F value  Pr(>F) 
agent       0.12494  1   1.3736  0.2856 
ratio       0.41714  2   2.2931  0.1821 
agent:ratio 0.22816  2   1.2542  0.3507 
Residuals   0.54573  6   
 
11.4.5 Effect of Transfection Buffer 
Multiway anova: 
Response: concentration 
              Sum Sq Df  F value   Pr(>F)    
buffer       0.00690  1   0.2985  0.60450    
ratio        0.83429  2  18.0608  0.00289 ** 
buffer:ratio 0.12130  2   2.6260  0.15162    
Residuals    0.13858  6                    
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
11.4.6 Transfection in Square-shaped Bottles 
Multiway anova: 
Response: concentration 
            Sum Sq Df  F value   Pr(>F)    
ratio        59.83  2   1.3806  0.321184    
scale       339.19  1  15.6538  0.007482 ** 
ratio:scale   9.37  2   0.2161  0.811653    
Residuals   130.01  6                     
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
